Brief: Ascentage Pharma Group International Announces Exclusive Option Deal With Takeda International
14/06/2024 14:10
June 14 (Reuters) - Ascentage Pharma Group International
6855.HK :
* EXCLUSIVE OPTION AGREEMENT WITH TAKEDA INTERNATIONAL
* EXCLUSIVE OPTION AGREEMENT FOR EXCLUSIVE LICENSE DEAL FOR
OLVEREMBATINIB (HQP1351)
* CO WILL RECEIVE OPTION PAYMENT OF US$100 MILLION UPON
SIGNING OF
EXCLUSIVE OPTION AGREEMENT
Further company coverage: 6855.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascentage Pharma International
See all newsBrief: Ascentage Pharma Group Says Lisaftoclax Granted Breakthrough Therapy Designation In China
China's Ascentage Pharma climbs as chairman buys shares on market
Brief: Ascentage Pharma Group International's Chairman Buys 38,630 Shares
Brief: Ascentage Pharma Group International Posts H1 Net Loss Attributable RMB816.7 Million
China's Ascentage Pharma H1 revenue rises 29% on Lisaftoclax ramp-up